Cargando…

Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA-induced breast cancer cell invasion via PLCγ2/PKCβ/NF-κB/AP-1-dependent matrix metalloproteinase-9 activation

Bruton's agammaglobulinemia tyrosine kinase (BTK) is an important cytoplasmic tyrosine kinase involved in B-lymphocyte development, differentiation, and signaling. Activated protein kinase C (PKC), in turn, induces the activation of mitogen-activated protein kinase (MAPK) signaling, which promo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jeong-Mi, Park, Jinny, Noh, Eun-Mi, Song, Hyun-Kyung, Kang, Sang Yull, Jung, Sung Hoo, Kim, Jong-Suk, Park, Byung-Hyun, Lee, Young-Rae, Youn, Hyun Jo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962096/ https://www.ncbi.nlm.nih.gov/pubmed/33760219 http://dx.doi.org/10.3892/or.2021.8007

Ejemplares similares

Downregulation of matriptase suppresses the PAR-2/PLCγ2/PKC-mediated invasion and migration abilities of MCF-7 breast cancer cells
por: Kim, Jeong-Mi, et al.
Publicado: (2021)

Bruton's Agammaglobulinemia and COVID-19
por: Hovey, Justin G, et al.
Publicado: (2020)

Correction: Bruton's Agammaglobulinemia and COVID-19
por: Hovey, Justin G, et al.
Publicado: (2021)

A novel Bruton’s tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia
por: Zheng, Bixia, et al.
Publicado: (2014)

Vegetative Skin Lesions in Patient with Bruton's Agammaglobulinemia
por: Fidanzi, Cristian, et al.
Publicado: (2023)

Sulforaphane controls TPA-induced MMP-9 expression through the NF-κB signaling pathway, but not AP-1, in MCF-7 breast cancer cells
por: Lee, Young-Rae, et al.
Publicado: (2013)

Presentation of a case of Bruton type primary agammaglobulinemia in Guinea
por: Condé, Kaba, et al.
Publicado: (2020)

Clinical characteristics and prenatal diagnosis for 22 families in Henan Province of China with X-linked agammaglobulinemia (XLA) related to Bruton’s tyrosine kinase (BTK) gene mutations
por: Gao, Shanshan, et al.
Publicado: (2020)

Novel BTK Mutation in Patient with Late Diagnosis of X-Linked Agammaglobulinemia
por: Kalkat, Amanpreet, et al.
Publicado: (2023)

Suppression of TPA-induced cancer cell invasion by Peucedanum japonicum Thunb. extract through the inhibition of PKCα/NF-κB-dependent MMP-9 expression in MCF-7 cells
por: KIM, JEONG-MI, et al.
Publicado: (2016)

Intrahepatic cholestasis in Bruton's agammaglobulinemia receiving mesalamine for co-morbid Crohn's disease
por: Actis, Giovanni Clemente, et al.
Publicado: (2014)

Salvia miltiorrhiza extract inhibits TPA-induced MMP-9 expression and invasion through the MAPK/AP-1 signaling pathway in human breast cancer MCF-7 cells
por: Kim, Jeong-Mi, et al.
Publicado: (2017)

X-Linked Agammaglobulinemia Case with TH Domain Missense Mutation in Bruton Tyrosine Kinase
por: Agrebi, Nourhen, et al.
Publicado: (2021)

Investigation of a synonymous mutation in Btk in a patient with agammaglobulinemia: A case report
por: Srinivasan, Cindy, et al.
Publicado: (2023)

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate
por: Wang, Qi, et al.
Publicado: (2015)

DHA blocks TPA-induced cell invasion by inhibiting MMP-9 expression via suppression of the PPAR-γ/NF-κB pathway in MCF-7 cells
por: Hwang, Jin-Ki, et al.
Publicado: (2017)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
por: Ariza, Yuko, et al.
Publicado: (2019)

Novel deletion mutation in Bruton’s tyrosine kinase results in X-linked agammaglobulinemia: A case report
por: Hu, Xiao-Mei, et al.
Publicado: (2020)

Case report: Evolution of pulmonary manifestations and virological markers in critical COVID-19 infection in Bruton’s agammaglobulinemia
por: Rise, Nina, et al.
Publicado: (2022)

A novel BTK gene mutation, c.82delC (p.Arg28 Alafs(*)5), in a Korean family with X-linked agammaglobulinemia
por: Lee, Jeongeun, et al.
Publicado: (2016)

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
por: Bam, R, et al.
Publicado: (2014)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA)
Publicado: (1994)

Crotonis Fructus Extract Inhibits 12-O-Tetradecanoylphorbol-13-Acetate-Induced Expression of Matrix Metalloproteinase-9 via the Activator Protein-1 Pathway in MCF-7 Cells
por: Song, Hyun-Kyung, et al.
Publicado: (2017)

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
por: Ringheim, Garth E., et al.
Publicado: (2021)

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
por: Zucha, Muhammad Ary, et al.
Publicado: (2015)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

Role of the Btk-PLCγ2 Signaling Pathway in the Bone Destruction of Apical Periodontitis
por: Wang, Lina, et al.
Publicado: (2019)

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
por: Ghoshdastidar, Krishnarup, et al.
Publicado: (2020)

Protein tyrosine phosphatase controls breast cancer invasion through the expression of matrix metalloproteinase-9
por: Hwang, Bo-Mi, et al.
Publicado: (2013)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
por: Yang, Xuedong, et al.
Publicado: (2019)

Bruton’s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma
por: Yeh, Chi-Tai, et al.
Publicado: (2021)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor
por: Xiao, Zhou-Peng, et al.
Publicado: (2023)

Selective regulation of osteoclast adhesion and spreading by PLCγ/PKCα-PKCδ/RhoA-Rac1 signaling
por: Kim, Jin-Man, et al.
Publicado: (2018)

The B Cell Antigen Receptor Controls Integrin Activity through Btk and PLCγ2
por: Spaargaren, Marcel, et al.
Publicado: (2003)

A Novel BTK Gene Mutation in a Child With Atypical X-Linked Agammaglobulinemia and Recurrent Hemophagocytosis: A Case Report
por: Han, Shu-Ping, et al.
Publicado: (2019)

The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacement
por: Cavaliere, Filomena Monica, et al.
Publicado: (2017)

Bruton's Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages
por: Strijbis, Karin, et al.
Publicado: (2013)

Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype
por: Sala, Luca, et al.
Publicado: (2019)

Bruton tyrosine kinase (BTK) may be a potential therapeutic target for interstitial cystitis/bladder pain syndrome
por: Wang, Guang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ik7rfc9fkss64lao18vgs9h6nm